Novo Nordisk
2025-05-07T05:30:45Z
2025-05-07T05:30:45Z
7 May 2025 - Financial report for the period 1 January 2025 to 31 March 2025
PROFIT AND LOSS | Q1 2025 | Q1 2024 | Growth as reported | Growth at CER* |
DKK million | ||||
Net sales | 78,087 | 65,349 | 19% | 18% |
Operating profit | 38,791 | 31,846 | 22% | 20% |
Net profit | 29,034 | 25,407 | 14% | N/A |
Diluted earnings per share (in DKK) | 6.53 | 5.68 | 15% | N/A |
* CER: Constant exchange rates (average 2024). |
Lars Fruergaard Jørgensen, president and CEO: "In the first quarter of 2025, we delivered 18% sales growth and continued to expand the reach of our innovative GLP-1 treatments. However, we have reduced our full-year outlook due to lower-than-planned branded GLP-1 penetration, which is impacted by the rapid expansion of compounding in the US. We are actively focused on preventing unlawful and unsafe compounding and on efforts to expand patient access to our GLP-1 treatments. Within R&D, we are pleased to have completed the last pivotal trial for our next-generation obesity treatment, CagriSema, and to have filed for US approval of oral semaglutide 25 mg, with the potential to be the first oral GLP-1 treatment for obesity."
On 7 May 2025 at 13.00 CET, corresponding to 07.00 am EST, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under 'Investors' (the contents of the company's website do not form a part of this Form 6-K).
About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, X, LinkedIn and YouTube.
Contacts for further information | |
Media: | |
Ambre James-Brown +45 3079 9289 abmo@novonordisk.com | Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com |
Investors: | |
Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com | Sina Meyer +45 3079 6656 azey@novonordisk.com |
Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com | Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com |
Max Ung +45 3077 6414 mxun@novonordisk.com |
Company announcement No 14 / 2025
Attachment